Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00035893 · ClinicalTrials.gov registry record · Phase 2
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
A Phase 2 study of HIV Infection and HIV Seropositivity, sponsored by AIM ImmunoTech.
- Completed
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 10
- Study locations
NCT00035893 is a Phase 2 study of HIV Infection and HIV Seropositivity that has completed, run by AIM ImmunoTech. The registered enrollment target is 40 participants, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (83% lower). The trial reports 10 study locations across 6 states.
The verdict
NCT00035893, a Phase 2 study of HIV Infection and HIV Seropositivity, has completed, sponsored by AIM ImmunoTech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA \< 50 copies/ml (PCR) and CD4 levels \> 400.
Conditions Studied
Interventions
- DRUG poly I-poly C12U
Study Locations (10)
Florida
- Julia Torres, MD - Fort Lauderdale
- Allied Clinical Trials - Miami
- Scott Ubillos, MD - Tampa
California
- Orange County Center for Special Immunology - Fountain Valley
- AltaMed Health Services Corporation - Los Angeles
New Jersey
- St. Michael's Medical Center - Newark
- Christopher Lucasti, D.O. - Somers Point
Connecticut
- Circle Medical Center - Norwalk
District of Columbia
- Dupont Circle Physicians Group - Washington D.C.
Pennsylvania
- W. Chris Woodward, DO - Reading
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2001-05 |
| Est. Completion | 2006-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00035893
The ClinicalTrials.gov registry entry for NCT00035893 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 242-participant average among 73 other HIV Infection trials with a reported enrollment target (83% lower). The listed sponsor is AIM ImmunoTech, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with HIV Infection appearing as the primary indexed condition, and to 1 intervention - of which poly I-poly C12U is the first listed.
NCT00035893 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, New Jersey.
Frequently Asked Questions
What is clinical trial NCT00035893 about?
NCT00035893 is a clinical study titled "The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART". This is an open-label, prospective, randomized, controlled study of the safety and efficacy including clinical, immunologic, and virologic assessments of adding Ampligen to a Strategic Therapeutic Intervention (STI) of HAART in patients with plasma HIV RNA \< 50 copies/ml (PCR) and CD4 levels \> 400...
What is the current status of trial NCT00035893?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2001-05. Estimated completion is 2006-08.
What conditions does trial NCT00035893 study?
This clinical trial studies the following conditions: HIV Infection, HIV Seropositivity.
What interventions are being tested in trial NCT00035893?
The interventions under investigation include: poly I-poly C12U (DRUG).
Who is sponsoring clinical trial NCT00035893?
This trial is sponsored by AIM ImmunoTech, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00035893 being conducted?
This trial has 10 study locations across California, Connecticut, District of Columbia, Florida, New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer
RECRUITING · Phase 2
-
Surgery in Treating Patients With Early Stage Anal Canal or Perianal Cancer and HIV Infection
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Teropavimab and Zinlirvimab in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults With HIV-1 Infection
ACTIVE NOT RECRUITING · Phase 2
-
Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
COMPLETED · Phase 2
-
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
COMPLETED · Phase 2
-
A Clinical Study Of An Investigational Regimen Including Marketed HIV Drugs In HIV-1 Pediatric Subjects Ages 2-18 Years
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.